DIBAC-GGFG-NH₂CH₂-Dxd (CAS: 2758875-01-1) is a linker-payload used in antibody-drug conjugates (ADCs), combining a cleavable peptide linker and a cytotoxic agent derived from camptothecin (Dxd). It supports targeted cancer therapy by enabling precise drug delivery through site-specific conjugation and controlled drug release.
Key Features:
- DIBAC Group: Enables copper-free click chemistry via strain-promoted azide-alkyne cycloaddition (SPAAC), ensuring efficient bioconjugation.
- GGFG Peptide Linker: Provides an enzyme-cleavable sequence for controlled payload release in targeted cells.
- Dxd (Camptothecin Derivative): Acts as a potent topoisomerase I inhibitor, inducing cancer cell death.
Applications:
- Antibody-Drug Conjugates (ADCs): Serves as a payload-linker in ADC development, enabling targeted cancer therapy with minimized side effects.
- Bioconjugation: Supports protein-drug conjugation using copper-free click chemistry for therapeutic and diagnostic purposes.
This compound plays a crucial role in developing next-generation cancer therapies by combining targeted delivery with a highly potent cytotoxic payload.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
